Vascular endothelial growth factor‐C gene therapy restores lymphatic flow across incision wounds

Wiley - Tập 18 Số 14 - Trang 1707-1709 - 2004
Anne Saaristo1,2, Tuomas Tammela2, Juri M. Timonen3, Seppo Ylä‐Herttuala4, Erkki Tukiainen3, Sirpa Asko‐Seljavaara3, Kari Alitalo2
1Department of Surgery Paijat-Hame Central Hospital Lahti
2Molecular/Cancer Biology Laboratory and Ludwig Institute for Cancer Research, Biomedicum Helsinki and Helsinki University Central Hospital, University of Helsinki 00014 Helsinki
3Department of Plastic Surgery, Helsinki University Central Hospital, Helsinki
4A. I. Virtanen Institute, Department of Medicine and Gene Therapy Unit University of Kuopio University of Kuopio Finland

Tóm tắt

ABSTRACTEdema and insufficient blood perfusion are common problems in reconstructive surgery. The blood vasculature is reconstructed in microvascular flaps, whereas lymphatic vessel function is lost after surgical incision. Here, we demonstrate that vascular endothelial growth factor C (VEGF‐C) gene transfer can be used to reconstruct a lymphatic vessel network severed by incision of skin flaps. We used adenoviral VEGF‐C gene transfer at the edges of epigastric skin flaps in mice. Our results show that VEGF‐C gene expression results in the formation of anastomoses between the lymphatic vessels of the skin flap and the surrounding lymphatic vasculature. Some spontaneous lymphangiogenesis also took place in the control mice, but the lymphatic vessels generated remained nonfunctional even 2 months postoperatively. In contrast, the VEGF‐C treated mice demonstrated persistent lymphatic vessel function during the 2 month follow‐up despite the transient nature of the adenoviral VEGF‐C gene expression. The restoration of lymphatic function by VEGF‐C in skin flaps provides new tools to promote vascular perfusion and to reduce tissue edema in skin and muscle flaps. These results have important implications for the prevention and treatment of surgically induced secondary lymphedema.

Từ khóa


Tài liệu tham khảo

Yla-Herttuala S., 2001, Gene therapy for coronary heart disease, J. Intern. Med., 250, 367, 10.1046/j.1365-2796.2001.00909.x

10.1038/415234a

Diaz-Sandoval L. J., 2003, Gene therapy for cardiovascular angiogenesis, Exp. Opin. Biol. Ther., 4, 599, 10.1517/14712598.3.4.599

10.1097/00006534-198312000-00003

10.1160/TH03-04-0200

10.1016/S0002-9440(10)65582-4

10.1084/jem.20020587

10.1161/01.RES.0000073584.46059.E3

10.1038/75997

10.1086/303019

10.1073/pnas.221449198

10.1096/fj.02-0401fje

10.1172/JCI15830

10.1111/j.1749-6632.2002.tb04868.x

10.1097/00006534-199606000-00021

Yang Y., 1996, Immune response to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo, Gene Ther., 3, 137

Bellman S., 1958, Regeneration of surgically divided lymph vessels. An experimental study on the rabbit ear, Acta Chir. Scand., 116, 99

10.1016/S0002-9440(10)65021-3

10.1007/s00441-004-0889-3

10.1097/00000637-200208000-00009

Rinsch C., 2001, Delivery of FGF-2 but not VEGF by encapsulated genetically engineered myoblasts improves survival and vascularization in a model of acute skin flap ischemia, Gene Ther., 7, 523, 10.1038/sj.gt.3301436

10.1002/micr.10140

10.1038/nm0603-694

Thông tin
Thông tin xuất bản

Wiley

Tập 18 Số 14

1707-1709

Thông tin tác giả